IDEAYA Biosciences reported revenue of $8.86M and net income of -$113.63M for the quarter ended Jun 2026. This income statement covers 33 quarters of results from Jun 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||||||
| Revenue | 8.98M | 2.96M | 11.36M | 5.85M | 29.70M | 4.02M | 7.88M | 3.54M | 8.04M | 3.92M | 7.00M | 207.83M | 10.88M | 6.56M | 8.86M | ||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 15.50M | 16.11M | 19.66M | 22.80M | 22.37M | 24.71M | 27.86M | 29.18M | 33.70M | 38.77M | 42.80M | 54.53M | 57.15M | 140.18M | 70.89M | 74.23M | 82.99M | 86.60M | 95.73M | 108.69M | |||||||||||||
| Selling, General & AdministrativeSG&A | 5.19M | 5.22M | 5.92M | 5.55M | 6.67M | 5.75M | 6.30M | 7.08M | 7.86M | 7.07M | 8.21M | 10.39M | 9.74M | 10.96M | 13.50M | 14.58M | 16.39M | 18.85M | 19.38M | 22.46M | |||||||||||||
| Operating ExpensesOpex | 20.69M | 21.33M | 25.58M | 28.35M | 29.04M | 30.46M | 34.16M | 36.25M | 41.56M | 45.84M | 51.02M | 64.93M | 66.89M | 151.14M | 84.39M | 88.81M | 99.38M | 105.45M | 115.10M | 131.15M | |||||||||||||
| Operating IncomeOp. Inc | -11.71M | -18.37M | -14.22M | -22.50M | 0.66M | -26.44M | -26.28M | -32.71M | -33.53M | -41.92M | -51.02M | -64.93M | -66.89M | -144.14M | -84.39M | -88.81M | 108.45M | -94.57M | -108.54M | -122.29M | |||||||||||||
| EBIT | -11.71M | -18.37M | -14.22M | -22.50M | 0.66M | -26.44M | -26.28M | -32.71M | -33.53M | -41.92M | -51.02M | -64.93M | -66.89M | -144.14M | -84.39M | -88.81M | 108.45M | -94.57M | -108.54M | -122.29M | |||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | -0.05M | -0.66M | -2.09M | -0.82M | -0.37M | 1.13M | 1.47M | 0.23M | 0.43M | 1.31M | -1.49M | -0.49M | 5.25M | -3.02M | 0.77M | -0.06M | 0.53M | 0.21M | -2.76M | -1.18M | |||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | |||||||||||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | 0.13M | 0.16M | 0.21M | 0.44M | 0.95M | 2.24M | 2.64M | 4.78M | 6.09M | 7.96M | 11.45M | 12.15M | 15.07M | 13.83M | 12.21M | 11.31M | 10.79M | 11.30M | 10.01M | 9.84M | |||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||
| EBT | -11.76M | -19.03M | -16.31M | -23.32M | 0.29M | -25.31M | -24.81M | -32.48M | -33.10M | -40.60M | -52.50M | -65.42M | -61.64M | -147.16M | -83.62M | -88.87M | 108.98M | -94.36M | -111.31M | -123.47M | |||||||||||||
| Profit After TaxPAT | -11.63M | -18.87M | -16.11M | -22.88M | 1.61M | -23.07M | -23.64M | -27.93M | -27.44M | -33.95M | -41.06M | -53.27M | -51.82M | -130.31M | -72.18M | -77.56M | 119.78M | -83.27M | -101.30M | -113.63M | |||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -11.76M | -19.03M | -16.31M | -23.32M | 0.29M | -25.31M | -24.81M | -32.48M | -33.10M | -40.60M | -52.50M | -65.42M | -61.64M | -147.16M | -83.62M | -88.87M | 108.98M | -94.36M | -111.31M | -123.47M | |||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -11.76M | -19.03M | -16.31M | -23.32M | 0.29M | -25.31M | -24.81M | -32.48M | -33.10M | -40.60M | -52.50M | -65.42M | -61.64M | -147.16M | -83.62M | -88.87M | 108.98M | -94.36M | -111.31M | -123.47M | |||||||||||||
| Income towards Parent CompanyParent Net Inc | -11.76M | -19.03M | -16.31M | -23.32M | 0.29M | -25.31M | -24.81M | -32.48M | -33.10M | -40.60M | -52.50M | -65.42M | -61.64M | -147.16M | -83.62M | -88.87M | 108.98M | -94.36M | -111.31M | -123.47M | |||||||||||||
| Net Income towards Common StockholdersNet Income | -11.76M | -19.03M | -16.31M | -23.32M | 0.29M | -25.31M | -24.81M | -32.48M | -33.10M | -40.60M | -52.50M | -65.42M | -61.64M | -147.16M | -83.62M | -88.87M | 108.98M | -94.36M | -111.31M | -123.47M | |||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.31 | -0.54 | -0.42 | -0.60 | 0.01 | -0.61 | -0.51 | -0.58 | -0.55 | -0.71 | -0.70 | -0.84 | -0.72 | -1.80 | -0.95 | -1.00 | 1.23 | -1.07 | -1.25 | -1.34 | |||||||||||||
| EPS (Diluted) | -0.31 | -0.54 | -0.42 | -0.60 | 0.01 | -0.61 | -0.51 | -0.58 | -0.55 | -0.71 | -0.70 | -0.84 | -0.72 | -1.80 | -0.95 | -1.00 | 1.22 | -1.07 | -1.25 | -1.34 | |||||||||||||
| Shares Outstanding | 37.78M | 35.25M | 38.59M | 38.66M | 40.30M | 41.44M | 48.37M | 56.25M | 60.00M | 57.52M | 75.11M | 77.96M | 86.19M | 81.68M | 88.36M | 88.47M | 88.53M | 88.49M | 88.70M | 92.06M | |||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 37.77M | 35.25M | 38.59M | 38.66M | 41.11M | 41.44M | 48.37M | 56.25M | 60.00M | 57.52M | 75.11M | 77.96M | 86.19M | 81.68M | 88.36M | 88.47M | 89.69M | 88.49M | 88.70M | 92.06M | |||||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 38.46M | 38.53M | 38.64M | 38.70M | 48.09M | 48.19M | 48.39M | 57.44M | 58.63M | 65.04M | 74.76M | 76.09M | 86.36M | 86.50M | 87.57M | 87.64M | 87.67M | 87.80M | 87.86M | 96.38M | |||||||||||||
| EBITDA | -11.71M | -18.37M | -14.22M | -22.50M | 0.66M | -26.44M | -26.28M | -32.71M | -33.53M | -41.92M | -51.02M | -64.93M | -66.89M | -144.14M | -84.39M | -88.81M | 108.45M | -94.57M | -108.54M | -122.29M |